Esperion Therapeutics Inc (NASDAQ:ESPR)

6.70
Delayed Data
As of Sep 30
 -0.14 / -2.05%
Today’s Change
3.28
Today|||52-Week Range
11.92
+34.00%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$446.6M

Company Description

Esperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Contact Information

Esperion Therapeutics, Inc.
3891 Ranchero Drive
Ann Arbor Michigan 48108
P:(734) 887-3903
Investor Relations:

Employees

Shareholders

Other institutional56.15%
Mutual fund holders31.03%
Individual stakeholders23.41%

Top Executives

Sheldon L. KoenigPresident, Chief Executive Officer & Director
Ken FiorelliChief Technical Operations Officer
JoAnne Micale FoodyChief Medical Officer
William J. SasielaSenior Vice President-Clinical Development
Eric J. WarrenChief Commercial Officer